AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 NOV 13 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in Japan and the United States have developed a chimeric protein that may offer protection from a number of bacterial toxins.
Mi-Na Kweon and colleagues at Osaka University in Osaka, Protein Express and Higeta Shoyu Co. Ltd. in Chiba, and other institutions in Chiba, Tokyo, and Birmingham, Alabama, described their "novel nontoxic form of chimeric mucosal adjuvant that combines the A subunit of mutant cholera toxin E112K with the pentameric B subunit of heat-labile enterotoxin from enterotoxigenic Escherichia coli" (mCTA/LTB) in the November edition of the Journal of Infectious Diseases.
This construct helped protect animals from the effects of tetanus toxin and influenza infection, Kweon and coauthors reported.
The researchers used a murine model to evaluate the efficacy of mucosal mCTA/LTB administration. The Brevibacillus choshinensis expression system was used to develop this protein adjuvant, they noted.
Mice who received nasal immunization with mCTA/LTB and tetanus toxoid (TT) demonstrated potent and TT-specific mucosal immunoglobulin A (IgA) responses, in addition to significant and specific IgA and IgG serum activity, study data showed. Antibody activity triggered by immunization protected mice from otherwise lethal exposure to tetanus toxin. However, mCTA/LTB failed to induce relevant IgE ...
Source: HighBeam Research, Novel mucosal adjuvant safe, effective.